Nasdaq Technology

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 1:

U.S. stocks rallied in February, with the S&P 500 and the Nasdaq Composite Index recording the best month in nearly a decade. Meanwhile, the Dow Jones Industrial Average logged a four-month winning streak for the first time si

For Immediate ReleaseChicago, IL – March 1, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the finan

For Immediate ReleaseChicago, IL – March 1, 2024 – Today, Zacks Equity Research discusses Netflix NFLX, Warner Bros. Discovery WBD, Fox FOXA and Roku ROKU.

For Immediate ReleaseChicago, IL – March 1, 2024 – Today, Zacks Equity Research discusses United Therapeutics UTHR, Esperion Therapeutics. ESPR, Heron Therapeutics HRTX, Lyra Therapeutics LYRA and Aldeyra Therapeutics ALDX.

For Immediate ReleaseChicago, IL – March 1, 2024 – Today, Zacks Equity Research discusses Expeditors International of Washington EXPD, Matson MATX and Despegar.com, Corp. DESP.

For Immediate ReleaseChicago, IL – March 1, 2024 – Stocks in this week’s article are American Eagle Outfitters AEO, Central Garden & Pet Co. CENT, General Motors Co. GM, Vertiv Holdings Co. VRT and Toll Brothers, Inc. TOL.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts ofte

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings oft

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings oft

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings oft

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings oft

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings oft

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts ofte

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings oft

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings oft

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but

Amneal Pharmaceuticals (AMRX) reported $616.98 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 1.2%. EPS of $0.14 for the same period compares to $0.23 a year ago.

For the quarter ended January 2024, NetApp (NTAP) reported revenue of $1.61 billion, up 5.2% over the same period last year. EPS came in at $1.94, compared to $1.37 in the year-ago quarter.

The RealReal (REAL) reported $143.37 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 10.2%. EPS of -$0.07 for the same period compares to -$0.29 a year ago.